Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
- Symbol
- COYA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $118.23M
- 52 week range
- 3.71 - 7.75
Valuation
- Share price
- $5.04 (close of 2026-09-23)
- P/E (TTM)
- -4.71x
- Price to book
- 2.73x
- Price to free cash flow
- -7.52x
- Enterprise value
- $75.05M
- Book value per share
- $1.84
Price performance
| Period | Change |
|---|
| 1 day | +1.82% |
| 5 days | +8.39% |
| 1 month | +3.49% |
| 3 months | -6.49% |
| 6 months | +19.43% |
| Year to date | -13.10% |
| 1 year | -4.00% |
| 3 years | +25.37% |
| All time | +10.28% |
Profitability and growth
- Return on equity
- -49.33%
- Return on assets
- -42.49%
- Return on capital employed
- -51.17%
- Net margin
- -267.14%
- EBITDA margin
- -283.52%
- Revenue growth
- 123.57%
- Net income growth
- -42.64%
- Free cash flow growth
- -4.38%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -13.30%
- Current ratio
- 13.40x
- Net debt to EBITDA
- 1.87x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $7.95M
- EBITDA
- $-22.53M
- Net income
- $-21.23M
- Earnings per share
- $-1.27
- Shares outstanding
- 16.73M
Income statement by year
| Period end | Revenue | Net income | EPS |
|---|
| 2025-12-31 | $7.95M | $-21.23M | $-1.27 |
| 2024-12-31 | $3.55M | $-14.88M | $-0.98 |
| 2023-12-31 | $6.00M | $-7.99M | $-0.79 |
| 2022-12-31 | - | $-12.24M | $-4.73 |
| 2021-12-31 | - | $-4.89M | $-1.89 |
Margins and returns by year
| Period end | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | -267.14% | -49.33% | - |
| 2024-12-31 | -418.70% | -37.60% | -1335.89% |
| 2023-12-31 | -133.08% | -22.42% | -262.67% |
| 2022-12-31 | - | 145.88% | - |
| 2021-12-31 | - | -134.25% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $46.82M |
| 2024-12-31 | $38.34M |
| 2023-12-31 | $32.63M |
| 2022-12-31 | $5.93M |
| 2021-12-31 | $4.34M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-10.74M | $4.29M |
| 2024-12-31 | $-10.29M | $2.66M |
| 2023-12-31 | $-11.19M | $872.25K |
| 2022-12-31 | $-7.24M | $207.35K |
| 2021-12-31 | $-3.90M | $233.22K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-11
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-11 | Jun/2026 | - |
| 2026-05-12 | - | - |
| 2026-03-16 | - | - |
| 2025-11-12 | - | - |
| 2025-08-12 | - | - |
| 2025-05-13 | - | - |
| 2025-03-18 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- coyatherapeutics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades